Adenosine monophosphate-activated protein kinase (AMPK) serves as a central cellular energy sensor that modulates both metabolic homeostasis and inflammatory signalling. Upon activation by increases ...

Nowadays, the prevalence of sedentary lifestyles and high-caloric diets leads to an imbalance between energy intake and spending. Hence, in the last decades, we have observed a significant rise in ...

Credit: Shutterstock. PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. The Food and Drug Administration (FDA) has granted Fast Track ...

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 ...

Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate ...

SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the third quarter of 2026; SCYNEXIS is accepting ...